We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase.
- Authors
Bergenstal RM; Tamborlane WV; Ahmann A; Buse JB; Dailey G; Davis SN; Joyce C; Perkins BA; Welsh JB; Willi SM; Wood MA; STAR 3 Study Group; Bergenstal, Richard M; Tamborlane, William V; Ahmann, Andrew; Buse, John B; Dailey, George; Davis, Stephen N; Joyce, Carol; Perkins, Bruce A
- Abstract
OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
- Publication
Diabetes Care, 2011, Vol 34, Issue 11, p2403
- ISSN
0149-5992
- Publication type
journal article
- DOI
10.2337/dc11-1248